Sarclisa (Isatuximab-Irfc) for Myeloma

Overview
Sarclisa is approved by the U.S. Food and Drug Administration (FDA) for use in adults with multiple myeloma. It is indicated for individuals who have previously received at least two therapies, including lenalidomide and a proteasome inhibitor, and is prescribed in combination with pomalidomide and dexamethasone. Additionally, Sarclisa is approved for use with carfilzomib and dexamethasone in individuals with relapsed or refractory multiple myeloma after one to three prior therapies. Sarclisa can also be used in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed individuals who are not eligible for an autologous stem cell transplant. Sarclisa is also known by its drug name, isatuximab-irfc.

Sarclisa is a CD38-directed cytolytic antibody, which targets the CD38 protein found on the surface of myeloma cells. By binding to CD38, Sarclisa helps the immune system recognize and destroy these cancer cells.

How do I take it?
Prescribing information states that Sarclisa is administered as an intravenous (IV) infusion. The dosing schedule depends on the specific combination therapy prescribed. Before each infusion, a person will be premedicated with dexamethasone, acetaminophen, H2 antagonists, and diphenhydramine to reduce the risk of infusion-related reactions. Sarclisa should be administered exactly as prescribed by a healthcare provider.

Side effects
According to prescribing information, common side effects of Sarclisa vary depending on the combination therapy and may include upper respiratory tract infections, infusion-related reactions (such as fever or chills), diarrhea, fatigue, musculoskeletal pain, dyspnea (breathing difficulties), and pneumonia. Other side effects can include peripheral sensory neuropathy (numbness or tingling in the extremities), constipation, peripheral edema (swelling), rash, and insomnia. Common blood-related side effects include decreased hemoglobin (a protein in red blood cells), decreased neutrophils (a type of white blood cell), decreased lymphocytes (another type of white blood cell), and decreased platelets (cells involved in clotting).

Rare but serious side effects may include severe infections, neutropenia (low neutrophil count), second primary malignancies (new cancers developing after treatment), and serious infusion-related reactions (such as allergic reactions). Sarclisa may also interfere with certain blood tests used to monitor multiple myeloma, such as tests for M-protein levels and blood typing for transfusions.

For more information about this treatment, visit:

Sarclisa (Isatuximab-Irfc) Injection, for Intravenous Use — U.S. Food & Drug Administration

Sarclica — Drugs.com